Results 221 to 230 of about 181,664 (310)

Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma. [PDF]

open access: yesIn Vivo
Hur JY   +14 more
europepmc   +1 more source

Aniridia‐associated keratopathy: Clinical and molecular mechanisms of disease progression and emerging therapeutic targets

open access: yesActa Ophthalmologica, EarlyView.
Abstract Congenital aniridia is a rare genetic disorder primarily caused by pathogenic variants of the PAX6 gene. It leads to various panocular anomalies, including aniridia‐associated keratopathy (AAK). This review highlights recent insights into its pathogenesis, focusing on clinical staging, microstructural changes in the cornea and molecular ...
N. Szentmáry   +27 more
wiley   +1 more source

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study. [PDF]

open access: yesCancers (Basel)
Jung J   +23 more
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu   +3 more
wiley   +1 more source

Evolution of outcomes in autologous stem cell transplantation for hodgkin lymphoma over 2 decades at King Hussein cancer center. [PDF]

open access: yesAnn Hematol
Abdel Rahman Z   +12 more
europepmc   +1 more source

Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Research in multiple myeloma increasingly relies on surrogate end‐points to expedite approvals, yet these may not reflect patient priorities. We conducted a mixed‐methods study to identify outcomes valued by patients and clinicians and compare them with end‐points used in randomized controlled trials (RCTs).
Maria Mainou   +13 more
wiley   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy